The Award Winning over-the-counter (OTC) Pain Reliever, Cobroxin Advanced Topical Gel, is Now Available at Duane Reade Drugstores Located Throughout Metropolitan New York
DELRAY BEACH, Fla., Mar 01, 2010 -- Nutra Pharma's distributor, XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its award winning over-the-counter (OTC) pain reliever, Cobroxin Advanced Topical Gel, is now available at Duane Reade drugstores located throughout metropolitan New York. Duane Reade currently operates 253 stores in Manhattan.
"Duane Reade is considered one of the premier and fastest growing retail pharmacies in the United States and consistently ranks top in the industry for productivity, as measured by sales per square foot," explained Frank Rizzo, CEO of XenaCare Holdings. "We are excited to be working with the most recognized drugstore chain in New York City to introduce the Cobroxin Advanced Topical Gel to those suffering from moderate to severe chronic pain," he added.
Cobroxin is the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Many other Stage 2 drugs require prescriptions, including Tylenol 3, Percocet, and Vicodin. Cobroxin is currently available as an Advanced Oral Spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as an Advanced Topical Gel for treating joint pain and pain associated with repetitive stress and arthritis.
Additional benefits to Cobroxin include:
-- All Natural
-- Non-Addictive
-- Non-Narcotic
-- Non-Opiate
-- Long Lasting
XenaCare Holdings was granted a license by Nutra Pharma Corporation (OTCBB: NPHC), the biotechnology company that developed and currently manufactures Cobroxin, to market and distribute Cobroxin within the United States.
About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
Undiscovered Equities is currently offering a complimentary trial subscription.
To view our newsletter on a complimentary trial basis and take advantage of our other services go to www.undiscoveredequities.com and join our email list on our home page.
Sincerely,
Kevin McKnight1-800-404-8982Undiscovered Equities, Inc.101 Plaza Real, Suite 212Boca Raton, FL 33432www.undiscoveredequities.com
No comments:
Post a Comment